Par Drugs And Chemicals Limited (PAR) fundamentals
Par Drugs And Chemicals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as PAR (ISIN INE04LG01015). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Par Drugs And Chemicals Limited does
Par Drugs and Chemicals Limited is an India-based company engaged in manufacturing of active pharma ingredients (APIs) and fine chemicals for the domestic market as well as for exports to international markets. The Company manufactures a diverse range of antacid molecules. The Company’s products include magnesium hydroxide, magnesium trisilicate, magnesium carbonate, light magnesium oxide, magnesium oxide heavy, magnesium oxide USP, dried aluminum hydroxide gel, magaldrate, magnesium aluminum silicate hydrated, alma gate, hydrotalcite, aluminum hydroxide magnesium carbonate co-dried gel, aluminum-magnesium silicate BP, sodium aluminum silicate, precipitated silica, magnesium silicate, amorphous, colloidal silicon dioxide, and sucralfate USP. The Company owns and operates its manufacturing facilities at Bhavnagar in Gujarat. It has over four manufacturing blocks at Bhavnagar, which are for different products, having a capacity of approximately 9,700 metric tons per annum.
Valuation and market data
| Last close | ₹141.70 |
|---|---|
| Market capitalisation | ₹174 crore |
| Enterprise value | ₹151 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.76 |
| Price to sales (TTM) | 1.56 |
| Book value per share | ₹80.45 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Sep 16 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹108 crore | ₹17 crore | ₹13 crore | 0.00 |
| Mar 2025 | ₹103 crore | ₹18 crore | ₹13 crore | 10.86 |
| Mar 2024 | ₹96 crore | ₹20 crore | ₹15 crore | 11.78 |
| Mar 2023 | ₹96 crore | ₹15 crore | ₹11 crore | 9.21 |
| Mar 2022 | ₹75 crore | ₹13 crore | ₹9 crore | 7.49 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 73.4% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.1% |
| Retail and others | 26.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.